Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets

Biomed Pharmacother. 2022 May:149:112812. doi: 10.1016/j.biopha.2022.112812. Epub 2022 Mar 12.

Abstract

The clinical translation of therapeutic approaches to combat debilitating neurodegenerative conditions, such as Parkinson's disease (PD), remains as an urgent unmet challenge. The strong molecular association between the pathogenesis of traumatic brain injury (TBI) and the development of parkinsonism in humans has been well established. Therefore, a lot of ongoing research aims to investigate this pathology overlap in-depth, to exploit the common targets of TBI and PD for development of more effective and long-term treatment strategies. This review article intends to provide a detailed background on TBI pathophysiology and its established overlap with PD with an additional emphasis on the recent findings about their effect on perivascular clearance. Although, the traditional animal models of TBI and PD are still being considered, there is a huge focus on the development of combinatory hybrid animal models coupling concussion with the pre-established PD models for a better recapitulation of the human context of PD pathogenesis. Lastly, the therapeutic targets for TBI and PD, and the contemporary research involving exosomes, DNA vaccines, miRNA, gene therapy and gene editing for the development of potential candidates are discussed, along with the recent development of lesser invasive and promising central nervous system (CNS) drug delivery strategies.

Keywords: CNS Delivery; Concussion; Neurodegeneration; Parkinsonism; Parkinson’s disease; Traumatic Brain Injury.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain Concussion*
  • Brain Injuries, Traumatic* / therapy
  • Disease Models, Animal
  • Models, Animal
  • Neurodegenerative Diseases*
  • Parkinson Disease* / genetics
  • Parkinson Disease* / therapy